Allegations of Medical Malpractice in Chronic Opioid Analgesic Therapy Possibly Related to Collaborative/Split Treatment and the P-450 Enzyme System: Forensic Case Report

Pain Medicine

Volumn 11, Issue 9, 2010, Pages 1419-1425

  Fishbain, David A ^a,b,c   Lewis, John E ^a   Gao, Jinrun ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Douglas Gardens   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d State Farm Insurance   (United States)

Author keywords

Aberrant Drug Related Behaviors; Breaches of Standards; Chronic Opioid Analgesic Therapy; Chronic Pain; CYP 2D6; Intractable Pain; Medical Malpractice Allegations; Opioids; P 450 Enzyme System; Split Treatment; Standards of Medical Care

Indexed keywords

CYTOCHROME P450; DIAZEPAM; FLUOXETINE; NORDAZEPAM; OXYCODONE; PARACETAMOL; TRAZODONE;

ADULT; ANALGESIA; ARTICLE; AUTOPSY; BACKACHE; CASE REPORT; CAUSE OF DEATH; CHRONIC OPIOID ANALGESIC THERAPY; CHRONIC PAIN; CONSULTATION; CONTROLLED RELEASE FORMULATION; DEPRESSION; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DOSE TITRATION; DRUG INTOXICATION; DRUG METABOLISM; DRUG PROTEIN BINDING; FATALITY; FOLLOW UP; FORENSIC PATHOLOGY; HUMAN; INJURY; INTERVERTEBRAL DISKECTOMY; LAMINECTOMY; LUMBAR SPINE; MALE; MALPRACTICE; MASS FRAGMENTOGRAPHY; MEDICOLEGAL ASPECT; MORNING DOSAGE; POLYPHARMACY; POSTTRAUMATIC STRESS DISORDER; PSYCHIATRIST; RANGE OF MOTION; RISK ASSESSMENT; TABLET; TRIGGER POINT;

EID: 77956507624     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2010.00928.x     Document Type: Article

References (46)

1. Fishbain DA. Chapter 10: Chronic pain and addiction. Werner's Pain Management. A Practical Guide for Clinicians 2006, 117-39. Boswell MVCole BE. eds., 7th, edition, Boca Raton, FL, CRS, Taylor and Francis
2. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Steele-Rosomoff R. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 2008, 9(4):444-59.
3. Collins ED, Streltzer J. Should opioid analgesics be used in the management of chronic pain in opiate addicts. Am J Addict 2003, 12:93-100.
4. Shapiro RS. Health care providers' liability exposure for inappropriate pain management. J Law Med Ethics 1996, 24:360-64.
5. Fitzgibbon DR, Rathmell JP, Michna E, Stephens LS, Posner KL, Domino KB. Malpractice claims associated with medication management for chronic pain. Anesthesiology 2010, 12(4):948-56.
6. Fishbain DA, Cutler RB, Cole B. Medico-legal rounds: Medico-legal issues and alleged breaches of " standards of medical care" in opioid rotation to methadone: A case report. Pain Med 2003, 4(2):195-201.
7. Fishbain DA. Medico-legal rounds: Medico-legal issues and alleged breaches of " standards of medical care" in opioid tapering for alleged opioid addiction. Pain Med 2002, 3(2):135-42.
8. Fishbain DA, Lewis J, Cole B, Rosomoff RS, Rosomoff HL. Medico-legal rounds: Medico-legal issues and alleged breaches of " standards of medical care" in a patient motor vehicle accident, allegedly related to chronic opioid analgesic therapy; case report. J Opioid Manag 2007, 3(1):16-20.
9. Fishbain DA, Lewis J, Cole B, Rosomoff RS, Rosomoff HL. Alleged breaches of " standards of medical care" in a patient overdose death allegedly related to chronic opioid analgesic therapy: Case report. Application of the controlled substance model guidelines: Case report. Pain Med 2009, 10(3):565-72.
10. Fishbain DA, Lewis J, Gao J, Cole B, Steele-Rosomoff R. Alleged patient abandonment in chronic opioid analgesic therapy: Case report. Pain Med 2009, 10(4):722-9.
11. Fishbain DA, Lewis J, Gao J, Steele-Rosomoff R. Medical malpractice allegations of iatrogenic addiction in chronic opioid analgesic therapy: Forensic case reports. Pain Med 2010, DOI: 10.1111/j.1526-4637.2010.00938.x
12. Passik SD, Kirsh KL. Assessing aberrant drug-taking behaviors in the patient with chronic pain. Curr Pain Headache Rep 2004, 8:289-94.
13. Passik SD, Kirsh KL, McDonald MV. A pilot survey of aberrant drug-taking attitudes and behaviors in samples of cancer and AIDS patients. J Pain Symptom Manage 2000, 19:274-86.
14. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients. Preliminary validation of the opioid risk tool. Pain Med 2005, 6:432-42.
15. Chou R, Fanciullo GJ, Fine PG. Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009, 10(2):131-46.
16. Fleming MF, Davis J, Passik SD. Reported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients. Pain Med 2008, 9(8):1098-106.
17. Weissman DE, Maddox JD. Opioid pseudo-addiction-an iatrogenic syndrome. Pain 1989, 36(3):363-6.
18. Fishbain DA, Fishbain D, Lewis J. Genetic testing for enzymes of drug metabolism: Does it have clinical utility for pain medicine at the present time? A structured review. Pain Med 2004, 5(1):81-93.
19. Hadd A, Mellar D, Lagman R. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: Review and recommendations for avoiding adverse drug interactions. Support Care Cancer 2007, 15:251-7.
20. Armstrong SC, Cozza KL, Sandson N. Med-psych drug-drug interactions update. Six patterns of drug-drug interactions. Psychosom 2003, 44(3):255-8.
21. Armstrong SC, Cozza KL. Med-psych drug-drug interactions update. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: Theory and clinical realty. Part II Psychosom 2003, 44(6):515-9.
22. Sandson NB, Armstrong SC, Cozza KL. Med-psych drug-drug interactions update. An overview of psychotropic drug-drug interactions. Psychosom 2005, 46(5):464-94.
23. Alfaro CL, Lam WF, Simpson J, Ereshefsky L. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma concentration correlations. J Clin Pharmacol 2000, 40:58-66.
24. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993, 53(4):401-9.
25. Jannetto PJ, Wong SH, Gock SB. Pharmacogenomics as molecular autopsy for postmortem forensic toxicology; genotyping cytochrome P450 2D6 for oxycodone cases. J Anal Toxicol 2002, 26:438-47.
26. Burrow DL, Hagardorn AN, Harlan GC, Wallen EDB, Ferslew KE. A fatal drug interaction between oxycodone and clonazepam. J Forensic Sci 2003, 48(3):1-4.
27. Tennant F. Urine and blood tests. Pract Pain Manag 2007, (June):18-27.
28. Jung BF, Reidenberg MM. Clinical pharmacology grand rounds. Interpretation of opioid levels: Comparison of levels during chronic pain therapy to levels from forensic autopsies. Clin Pharmacol Ther 2005, 77(4):324-34.
29. Armstrong SC, Cozza KL, Benedek DM. Med-psych drug-drug interactions update. Psychosom 2002, 43(3):245-7.
30. Pharmaceutical Litigation Reporter 1999, Bocci v. Key Pharmaceuticals, Andrews Publications, Inc, March
31. Gallagher W. State of California v Fisher, Miller, Miller (1999-2003). Shasta County Superior Court criminal case 99F1134 [transcript from preliminary hearing
32. L Agee v. Purdue Pharmaceuticals. http://ca10.washburnlaw.edu/cases/2007/07/05-6002.htm, No. 05-6002 (D.C. No. CV-03-787-HE). W.D. Okla. United States Court of Appeals for the Tenth Circuit. Available at: (accessed July 19, 2007
33. Fishbain DA. Polypharmacy treatment approaches to the psychiatric and somatic comorbidities found in patients with chronic pain. Am J Phys Med Rehabil 2005, 84(3):s56-63.
34. Grant JE. When mixing drugs makes malpractice. Curr Psychiatry 2006, 5(4):52-4.
35. Devane CL. Antidepressant-drug interactions are potentially but rarely clinically significant. Neuropsychopharmacology 2006, 31(8):1594-604.
36. Perkins NA, Murphy JE, Malone DC, Armstrong EP. Performance of drug-drug interaction software for personal digital assistants. Ann Pharmacother 2006, 40(5):850-5.
37. Lahey W, Currie R. Regulatory and medico-legal barriers to interprofessional practice. J Interprof Care 2005, 10(1):197-223. suppl
38. Law estate v Simice. 1994, B.C.J. #979 (S.C
39. Matchar DB, Thakur M. Is genetic testing for cytochrome P450 polymorphism ready for implementation? Am Fam Physician 2007, 76(3):348-51.
40. Recommendations from the EGAPP working group: Testing for cytochrome P450 polymorphism in adults with nonpsychotic depression treated with selective serotonin inhibitors. Genet Med 2007, 9(12):819-25. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
41. Tchivileva IE, Lim PF, Smith SB. Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: A randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenet Genomics 2010, 20(4):129-38.
42. Walker JM, Farrey RJ. Are opioids associated with sleep apnea? A review of the evidence. Curr Pain Headache Rep 2009, 13:120-6.
43. Walker JM, Farrey RJ, Rhondeau SM. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 2007, 3:455-62.
44. Webster LR, Choi Y, Besai H, Webster L, Arant BJB. Sleep disordered breathing and chronic opioid therapy. Pain Med 2008, 9:425-32.
45. Mogri M, Khan MI, Grant BJG, Mador MJ. Central sleep apnea induced by acute ingestion of opioids. Chest 2008, 133(6):1484-8.
46. Jannetto PJ, Bratanow NC. Utilization of pharmacogenomics and therapeutic drug monitoring for opioids management. Pharmacogenomics 2009, 10(7):1157-67.